Medicare is set to begin negotiating lower prices with drug companies in the fall as a part of President Biden’s Inflation Reduction Act signed in 2022. However, some key players are hoping to avoid these negotiations altogether. The leading industry groups filed a lawsuit against the administration in June, claiming that the program violates the First and Fifth Amendments. Who will emerge victorious in this legal battle over drug prices remains to be seen.